We're pleased to announce that the 14th PVRI Annual World Congress on Pulmonary Vascular Disease will be held in Lima, Peru, from 30 January until 2 February 2020. Pre-meetings will take place on 29 January 2020.
Our Scientiﬁc Organising Committee has followed the successful programme format of our 2019 Congress, which offers even more possibility for discussion between speakers and the audience. We encourage networking between emerging and senior researchers, as well as stimulating interactions between basic and clinical research. 15 Travel Grants will be awarded for outstanding abstracts submitted.
The programme offers insights into cutting edge topics that cover local and global needs. We will round-up with pro and con debates. Importantly, our translational-oriented approach will reﬂect PVD research from bench to bedside and back. Keynote speakers will cover PVD-related ﬁelds, thereby opening new scientiﬁc horizons for all of us.
We are delighted to announce that this year's organising committee will comprise:
The congress will be held at the Swissotel Lima. All delegates will receive a unique booking link upon registration, which will include preferential rates and additional gratuities as negotiated by the PVRI.
We will let you know if your abstract has been accepted by 6 December 2019. Further information will be provided to authors on or before this date.
The PVRI will award a total of 15 Travel Grants. The best abstracts will receive a Travel Grant of $500. By submitting your abstract, you will automatically be considered for a Travel Grant. Further information will be available on our website.
We are pleased to be working with preferred partners in order to offer selected tour options for each of our delegates. Due to the popularity of each tour, it is advised that you book as far in advance as possible, to avoid disappointment.
Please note, that all tours are offered independently of the PVRI and should be organised between yourselves and the individual tour operator.
Through worldwide collaboration, we can begin to answer the question of a global disease.